이 보고서는 100개 이상의 기업 및 110개 이상의 의약품에 대한 종합적인 인사이트를 제공하여 코로나19 분야 경쟁 구도에 대한 종합적인 인사이트를 제공합니다. 본 보고서에서는 제품 유형, 개발 단계, 투여 경로, 분자 유형별 치료제 평가를 다루고 있습니다. 또한, 이 분야의 개발 동결 및 중단 상태의 파이프라인 제품에 대해서도 중점적으로 다루고 있습니다.
본 보고서에는 기업(치료제별, 개발단계별, 기술별)의 비교 평가가 포함되어 있습니다.
DelveInsight's, "COVID 19 - Competitive landscape, 2026," report provides comprehensive insights about 100+ companies and 110+ drugs in COVID 19 Competitive landscape. It covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
COVID 19: Understanding
COVID 19: Overview
COVID-19 is an infectious disease caused by a newly discovered coronavirus. It can affect your upper respiratory tract (sinuses, nose, and throat) or lower respiratory tract (windpipe and lungs). It spreads the same way other coronaviruses do, mainly through person-to-person contact. Infections range from mild to deadly. The main symptoms include: Fever , Coughing, Shortness of breath, Trouble breathing, Fatigue, Chills, sometimes with shaking, Body aches, Headache, Sore throat, Congestion/runny nose, Loss of smell or taste, Nausea, Diarrhea. The virus can lead to pneumonia, respiratory failure, heart problems, liver problems, septic shock, and death. Many COVID-19 complications may be caused by a condition known as cytokine release syndrome or a cytokine storm. This is when an infection triggers your immune system to flood your bloodstream with inflammatory proteins called cytokines. They can kill tissue and damage your organs.
SARS-CoV-2, the virus, mainly spreads from person to person. Most of the time, it spreads when a sick person coughs or sneezes. They can spray droplets as far as 6 feet away. If you breathe them in or swallow them, the virus can get into your body. Some people who have the virus don't have symptoms, but they can still spread the virus. You can also get the virus from touching a surface or object the virus is on, then touching your mouth, nose, or possibly your eyes. Most viruses can live for several hours on a surface that they land on. A study shows that SARS-CoV-2 can last for several hours on various types of surfaces: Copper (pennies, teakettles, cookware): 4 hours, Cardboard boxes: up to 24 hours, Plastic (milk containers, detergent bottles, subway and bus seats, elevator buttons):2 to 3 days, Stainless steel (refrigerators, pots and pans, sinks, some water bottles): 2-3 days.
Anyone can get COVID-19, and most infections are mild. The older you are, the higher your risk of severe illness. You also a have higher chance of serious illness if you have one of these health conditions: Chronic kidney disease, chronic obstructive pulmonary disease (COPD), a weakened immune system because of an organ transplant, obesity, serious heart conditions such as heart failure or coronary artery disease, sickle cell disease, Type 2 diabetes.
Conditions that could lead to severe COVID-19 illness include: Moderate to severe asthma, diseases that affect your blood vessels and blood flow to your brain, cystic fibrosis, high blood pressure, a weakened immune system because of a blood or bone marrow transplant, HIV, or medications like corticosteroids, dementia, liver disease, pregnancy, damaged or scarred lung tissue (pulmonary fibrosis), smoking, thalassemia, Type 1 diabetes.
Getting vaccinated against COVID-19 is a key part of prevention. But one should also take these steps: Washing hands often with soap and water or clean them with an alcohol-based sanitizer, practice social distancing, covering nose and mouth in public, don't touch face, clean and disinfect.
COVID 19: Company and Product Profiles (Marketed Therapies)
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world's largest biotechnology company and the global leader in in-vitro diagnostics. As a leading healthcare company, the company is doing all to support countries in their fight against COVID-19 and minimizing its impact. The company has developed a growing number of diagnostic solutions that help to detect and diagnose the infection, as well as providing digital support to healthcare systems. The company continue to identify, develop, and support therapies that can play a role in treating the disease. It is currently working with healthcare providers, laboratories, authorities, and organizations to help make sure patients continue to receive the tests, treatment and care they need during these challenging times. Building on a longstanding tradition of partnerships, it is working together with governments and others to make healthcare stronger and more sustainable in the future
Product Description: Tocilizumab
Actemra is a monoclonal antibody that reduces inflammation by blocking the interleukin-6 receptor. In the case of COVID-19 infection, the immune system can become hyperactive, which may result in worsening of disease. Actemra does not directly target SARS-COV-2. Actemra is a prescription medication given by intravenous infusion that is FDA-approved for multiple inflammatory diseases, including rheumatoid arthritis. Actemra is approved for use in multiple territories including the European Union, Japan, Bolivia, Chile, Guatemala, Ecuador, Honduras, Hong Kong, Myanmar, Peru, Philippines, the United Kingdom and Ukraine, provisionally approved in Australia, and authorized for emergency use in Ghana, Korea and the United States for defined patients hospitalized with severe or critical COVID-19. It has also been recommended and prequalified by the World Health Organization.
Bharat Biotech International Limited has established an excellent track record of innovation with more than 145 global patents, a wide product portfolio of more than 16 vaccines, 4 bio-therapeutics, registrations in more than 123 countries, and the World Health Organization (WHO) Pre-qualifications. Located in Genome Valley in Hyderabad, India, a hub for the global biotech industry, BBIL has built a world-class vaccine & bio-therapeutics, research & product development, Bio-Safety Level 3 manufacturing, and vaccine supply and distribution. Having delivered more than 4 billion doses of vaccines worldwide, BBIL continues to lead innovation and has developed vaccines for influenza H1N1, Rotavirus, Japanese Encephalitis (JENVAC(R)), Rabies, Chikungunya, Zika, Cholera, and the world's first tetanus toxoid conjugated vaccine for Typhoid. BBIL's commitment to global social innovation programs and the public-private partnership resulted in introducing path-breaking WHO pre-qualified vaccines such as BIOPOLIO(R), ROTAVAC(R), ROTAVAC(R) 5D, and Typbar TCV(R) combatting polio, rotavirus, typhoid infections, respectively.
Product Description: BBV154
BBV154 is a recombinant replication-deficient adenovirus vectored vaccine with a pre-fusion stabilized spike protein. This vaccine candidate was evaluated earlier in phase I and II clinical trials with successful results. BBV154 has been specifically formulated to allow intranasal delivery. In addition, the nasal delivery system has been designed and developed to be cost-effective in low and middle-income countries. BBV154 was developed in partnership with Washington University St Louis, which had designed and developed the recombinant adenoviral vectored constructs and evaluated them in preclinical studies for efficacy. Product development related to preclinical safety evaluation, large-scale manufacturing scale-up, formulation, and delivery device development, including human clinical trials, were conducted by Bharat Biotech. The Government of India partly funded product development and clinical trials through the Department of Biotechnology's, COVID Suraksha program. In September 2022, BBV154 COVID Vaccine is the first intranasal vaccine approved by DCGI for primary immunization against COVID-19 in the 18+ age group for restricted use in emergency situation being developed in the country under Mission COVID Suraksha and adds to our repertoire of COVID-19 vaccine.
COVID 19: Company and Product Profiles (Pipeline Therapies)
Bioxytran, Inc. is a clinical stage biotechnology company developing novel therapies targeting the treatment of significant unmet medical needs in virology, degenerative disease, and hypoxia. The leading drug candidate, Prolectin-M, is a new class of antiviral drug designed to antagonize galectins implicated in inflammatory, fibrotic, and malignant diseases. Bioxytran's other development programs are for pulmonary fibrosis and stroke treatment.
Product Description: ProLectin-M
ProLectin-M is an oral galectin antagonist that prevents the entry of the SARS-CoV-2 virus into human cells. In recent clinical trials the drug achieved a 100% responder's rate of negative PCR tests by day 7. In 3 days, the drug achieved an 88% responder's rate of negative PCR tests. The treated population experienced no viral rebounds during the 14-day observation period. The company is preparing for a phase 3 clinical trial in order to seek regulatory approval. Currently, the drug is in Phase III stage of Clinical trial evaluation for the treatment of COVID-19.
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections. Enanta's research and development programs include clinical candidates for the following disease targets: respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19) and hepatitis B virus (HBV). Enanta is also conducting research on a single agent targeting both RSV and human metapneumovirus (hMPV). Enanta receives royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie. Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic HCV infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET(R) (U.S.) and MAVIRET(R) (ex-U.S.) (glecaprevir/pibrentasvir).
Product Description: EDP-235
EDP-235, Enanta's lead 3CL protease inhibitor (also known as main protease or Mpro), which has Fast Track designation from the U.S. Food and Drug Administration, was specifically designed for the treatment of COVID-19. Preclinical data show that EDP-235 potently blocks the replication of SARS-CoV-2 in multiple cellular models. For example, in Vero cells, an EC90 of 11 and 5 nanomolar were observed for the Alpha and Omicron variant, respectively, positioning EDP-235 among the most potent direct-acting antivirals currently in development for SARS-CoV-2 infection. Preclinical studies also show that EDP-235 has favorable distribution into lung cells as well as other key target tissues. In addition to SARS-CoV-2, EDP-235 has potent antiviral activity against other human coronaviruses, enabling the potential for a pan-coronavirus treatment, including possibly coronaviruses that may infect human populations in the future. The drug is currently in Phase II stage of development for the treatment of patients with COVID 19.
Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases. SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, and mumps. SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1(R), which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu(R), to the Chinese government stockpiling program. SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations.
Product Description: SA55
SA55 is the broad-spectrum neutralizing antibody was founded by a research team led by Dr. Xiaoliang Xie, academician of the Chinese Academy of Sciences and Dr. Yunlong Cao, researcher at Peking University's Biomedical Pioneering Innovation Center. SA55 injection is a fully humanized antibody, which is screened from the blood of recovered SARS patients who have received three doses of COVID-19 vaccine, and then recombinantly expressed. As a prevention option, they have the advantage of rapidly increasing antibody levels post-administration and enjoy a longer half-life, making them suitable for immunocompromised individuals and those who would otherwise be ineligible for vaccination. China's National Medical Products Administration has approved SINOVAC's SA55 Nasal Spray for clinical trial in the prevention of COVID-19 infections, in April 2023. The drug is currently in Phase II stage of development for the treatment of patients with COVID 19.
Immorna is a rapidly expanding biotechnology company, focusing on the development of RNA-based therapeutics and vaccines. Immorna is utilizing multiple RNA platforms, including conventional, self-replicating and circular RNA. Since its founding in 2019, Immorna has built a robust CMC platform for RNA synthesis, purification, and analytical testing that is well suited for clinical and commercial development. In addition, with its state-of-the-art screening tools, Immorna has developed an arsenal of RNA delivery vehicles, including polymers and lipid nanoparticles featuring multiple proprietary ionizable cationic lipids suitable for intramuscular, intravenous and tissue-targeting delivery. Immorna has a growing intellectual property portfolio and a diverse RNA development pipeline spanning cancer immunotherapy, infectious diseases, rare genetic diseases, and medical cosmetology, and quickly advancing its oncology drug and infectious disease vaccine candidates into clinical stages.
Product Description: JCXH-221
JCXH-221 is a mono-valent yet broadly protective mRNA-LNP vaccine. Once administered, the single chain mRNA will translate and be spontaneously assembled into multimers that contain immune epitopes from several SARS-CoV-2 strains. The multimer configuration is believed to further enhance their immunogenicity. In preclinical testing, JCXH-221 elicited robust neutralizing antibodies against an assay of viral strains, including the ancestral, Beta, Delta, Omicron BA.1, BA.2.12.1, and BA.4/5. JCXH-221 is formulated with a thermal stable nanoparticle delivery system that is stable at 2-8°C for at least 18 months. JCXH-221, a lipid nanoparticle (LNP) complexed broadly protective mRNA vaccine against SARS-CoV-2 infection and diseases. The goal of this multi-center study is to assess the safety and immunogenicity of JCXH-221 in healthy adult subjects. The drug is currently in Phase I/II stage of development for the treatment of patients with COVID 19.
Immunome is a biopharmaceutical company that utilizes its proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics that are designed to change the way diseases are treated. The company's initial focus is developing therapeutics to treat oncology and infectious diseases, including COVID-19. Immunome's proprietary discovery engine identifies novel therapeutic antibodies and their targets by leveraging the highly educated components of the immune system, memory B cells, from patients whose bodies have learned to fight off their disease.
Product Description: IMM-BCP-01
IMM-BCP-01 is a three-antibody cocktail targeting non-overlapping regions of the Spike protein of SARS-CoV-2, including highly conserved, subdominant epitopes, which elicits both ACE2 and non-ACE2 dependent neutralization and induces natural viral clearance mechanisms, such as antibody dependent cellular cytotoxicity, complement activation and phagocytosis. Immunome has submitted an Investigational New Drug Application with the FDA and plans to initiate a placebo-controlled dose escalation study of IMM-BCP-01 in patients infected with SARS-CoV-2. This investigational work was funded by the U.S. Department of Defense's (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) in collaboration with the Defense Health Agency (DHA). The drug is currently in preclinical stage of development for the treatment of patients with COVID 19.
COVID 19 Analytical Perspective by DelveInsight
The Report provides in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing and acquisition - deals values trends. The sub-segmentation is described in the report which provide company-company collaboration (licensing/partnering), company academic collaboration and acquisition analysis in tabulated form.
The report comprises of comparative assessment of Companies (by therapy, development stage, and technology).
Current Treatment Scenario and Emerging Therapies:
Key Players
Key Products